News – Page 437 – Endpoints News

Gritstone bio secures PIPE financing as it unveils PhI data for vaccine candidate

3 years ago

GSK CEO Emma Walmsley triggers executive team revamp as vaccines chief Connor exits

3 years ago

Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates

3 years ago

Alto Neuroscience continues march toward the clinic with Series B, hoping to unveil data next year

3 years ago

Ex-Genentech scientist sentenced to six months in prison for stealing trade secrets

3 years ago

Updated: In broad retreat, GSK's new R&D leader abandons NY-ESO plans, pulls plug on cell therapy 2.0 alliances after ...

3 years ago

PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tumors

3 years ago

Prelude to buyout? Astellas picks up Taysha stock, two gene therapy programs for $50M

3 years ago

FDA inspection at Catalent’s Belgium facility uncovers data, equipment and other QC issues

3 years ago

J&J uncorks new Tremfya data in ulcerative colitis as its rival awaits an FDA decision

3 years ago

Pharma lobbying headed for record-breaking 2022, nonprofit says

3 years ago

Regeneron, Bayer's Eylea nabs six months of pediatric exclusivity as competition waits to enter the market

3 years ago

Genentech's newest ad campaign calls out the systemic racism fueling US health inequities

3 years ago

Developing gene therapies for neurodegenerative diseases: FDA finalizes guidance

3 years ago

Pfizer to make an almost $1B investment in its Dublin manufacturing facility — report

3 years ago

Recent use of Pfizer's Covid pill declines sharply compared to this summer

3 years ago

In $23M deal, Syncona adds ex-Biogen partner and 20-year-old gene therapy outfit AGTC to portfolio

3 years ago

Tricida bet its future on one last readout for its CKD drug. Now that’s all but gone

3 years ago

A Texas-Illinois cancer biotech searches for more Series B capital two years after extension

3 years ago

As top investor makes its play to grab lead drug, PhaseBio counters with Chapter 11, stalking-horse bid

3 years ago

After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win

3 years ago

The namesake behind Harvard’s Wyss Institute has made his fourth donation, this time to the tune of $350M

3 years ago

CD28 kills again? Mitch Gold’s plan to make cell therapy 2.0 history crashes after another patient dies of ...

3 years ago

Novartis takes another stride toward Alexion's turf with PhIII PNH win

3 years ago

First page Previous page 434 435 436437438 439 440 Next page Last page